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In the 2016 ESC guidelines, the diagnostic criteria for HFmrEF includes signs and symptoms of heart failure, an ejection fraction (EF) of 40-49%, elevated levels of natriuretic peptides and either relevant structural heart disease (i.e. left ventricular hypertrophy and/or left atrial enlargement) or diastolic dysfunction observed during echocardiography. 1 Interestingly, the last two criteria are also used to diagnose HFpEF; this new category could therefore be considered to constitute either pre-HFrEF or progressive HFpEF, assuming that HFpEF is a forerunner of HFrEF. 2, 3 This is supported by the fact that the ventricles of patients with HFpEF are not entirely normal and have certain contractile abnormalities. 4, 5 
Previous Changes in Classifications
In order to ascertain whether the new classification of HFmrEF is beneficial, it is useful to reflect on the introduction of the term 'HFpEF' . Prior to the formal identification of this group of patients as a distinct entity, clinicians were aware that some patients, mainly elderly hypertensive females, presented with clinical signs of heart failure but displayed normal left ventricular function on echocardiography. 6 Various aetiologies were suggested and these patients were initially labelled as having diastolic heart failure, as it was believed that these hypertensive patients had stiff ventricles that did not relax. 6 In the absence of any clinical evidence, clinicians often treated this group of patients in the same way as those with HFrEF, with varying results. 7 It was Gandhi et al. who first reported 38 patients presenting with hypertensive acute pulmonary oedema and preserved left ventricular function, both during the acute phase and after successful treatment of their acute presentation, thus demonstrating that these patients constituted a distinct entity. 8 This patient group was subsequently given many labels, such as 'diastolic heart failure' and 'heart failure with normal EF' . 9 Eventually, the American Heart Association and the ESC formally accepted the term 'HFpEF' .
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The formal recognition of HFpEF as a distinct entity has led to more focused research on this group of patients. It is now known that these patients are a heterogeneous group not limited to elderly hypertensive females and whose ventricles have normal systolic function with varying degrees of stiffness and diastolic abnormalities. 12 In addition, evidence now shows that many of the treatment modalities for treating HFrEF are ineffective for patients with HFpEF. 12 These findings have changed the management of and approach to dealing with patients with HFpEF, although there are admittedly still many unanswered questions. 13 In a similar manner, despite the possible initial reluctance to accept another category of heart failure patients, the decision by the ESC to define HFmrEF may help to increase understanding of this disease and improve its treatment, particularly for patients who fall in between the two previous categories.
Current Approaches to Diagnosis and Management
Clinicians familiar with the management of heart failure patients will know that individuals with HFmrEF are often difficult to treat. In a way, they are somewhat similar to HFpEF patients whereby the symptoms of heart failure appear disproportional to the level of reduced EF; moreover, these patients do not often respond as well to diuretics, angiotensinconverting enzyme inhibitors or β-blockers.
14 Similar to the treatment that HFpEF patients received prior to breakthroughs in the understanding of the disease, HFmrEF patients are still treated with similar management plans to those of HFrEF patients. 15 Although there is often no evidence to back up these management plans, clinicians tend to rely on their clinical experience. Perhaps time will tell whether these patients are more likely to respond to conventional heart failure treatments or whether there is a need for more specific treatment modalities. Currently, the ESC guidelines have combined the management of patients with HFmrEF with that of HFpEF patients. 1 A major problem in the management of HFpEF, and now HFmrEF as well, is establishing the diagnosis. 16 There is still some reluctance to label a patient with preserved left ventricular function as having heart failure; as such, HFpEF and HFmrEF patients are often underdiagnosed. 16 These patients sometimes undergo multiple tests to rule out respiratory and ischaemic causes of breathlessness before ultimately being diagnosed with heart failure. Moreover, HFpEF and HFmrEF patient groups are heterogeneous and often have multiple comorbidities that can confuse the diagnosis. 12 There is a danger of both the overand underdiagnosis of heart failure. Epidemiological studies have shown that the incidence of HFpEF appears to be on the rise. 17, 18 This could potentially be explained by the developing awareness of HFpEF on the part of clinicians and their increased willingness to make this diagnosis now that it has been officially recognised.
Opportunities for Further Research
With the previously undefined group of HFmrEF patients now having been legitimised with an official name, albeit one difficult to articulate properly, it can be hoped that this will spur research focusing specifically on this patient group. 19 Currently, it is unknown whether these patients have a milder version of HFrEF, if HFmrEF indicates those with HFpEF whose EF is now deteriorating or indeed if it is simply a part of the heart failure continuum. 19 Along those lines, it is not clear whether aggressive treatment of HFpEF would prevent patients from progressing to HFmrEF or whether aggressive management of HFmrEF would prevent patients from deteriorating to HFrEF. More research is therefore justified. This change in nomenclature gives rise to many questions that clinicians have perhaps always asked themselves, but never had the chance to openly query; these can hopefully now be answered, perhaps via large-scale clinical trials.
Alternative Classifications of Heart Failure
It must be noted that the use of EF as a method of classifying heart failure is not universally agreed upon. De Keulenaer et al. argue that HFpEF and HFrEF are overlapping phenotypes within the spectrum of heart failure and that the use of EF to classify heart failure is
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Sounding Board | e25 not accurate. 3 They suggest that this classification came about primarily because early heart failure drug trials included patients with low EF, who were considered a high-risk group, in order to produce statistically significant results. 3 Subsequently, an emphasis on evidence-based medicine has automatically led to the use of cut-off values derived from the results of these trials. Another suggestion is that the disease be classified based on aetiology or physiological abnormalities, as well as the clinical presentation of acute or chronic heart failure symptoms, as this affects management choices. 9 Furthermore, by using pathophysiology to classify heart failure, other researchers have proposed the use of biomarkers either alone or in combination with echocardiography in order to guide therapy and management choices, instead of relying entirely on EF measurements.
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Conclusion
Despite the announcement by the ESC of yet another category of heart failure patients with a tonguetwisting acronym, it is unlikely that the clinical management of this new HFmrEF patient group will change immediately. However, this new classification does define another subset of heart failure patients on whom additional and more focused research can now be conducted. Ideally, this will ensure increased understanding of this patient group in order to improve and effectively tailor management approaches.
